octuria QOL evaluation in OAB patients treated with Oxybutinin & Mirabegron study
- Conditions
- overactive bladder
- Registration Number
- JPRN-UMIN000024234
- Lead Sponsor
- Department of Urology, school of medicine, Shinshu university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 120
Not provided
(1) Patients in the study drug administration proposed site with a skin disease and skin abnormalities. (2) Patients with residual urine volume greater than 100mL. (3) Patients with a difficulty in going to the bathroom without the assistance. (4) Patients with a history of hypersensitivity of Oxybutynin hydrochloride or Mirabegron. (5) Patients receiving flecainide acetate or propafenone hydrochloride. (6) Patients with severe blood, liver, kidney disease and severe arrhythmia, suffering from cardiovascular diseases such as congestive heart failure. (7) Patients with hypokalemia (less than 3.5mEq / L). (8) Patients with paralytic ileus, ulcerative colitis, stomach atony, patients suffering from gastrointestinal diseases, such as bowel atony. (9) Patients with Parkinson's syndrome, dementia, suffering from psychiatric and neurological disorders or cerebrovascular disorders such as myasthenia gravis. (10) Patients with a glaucoma. (11) Patients with a hyperthyroidism. (12) Patients with malignant tumors. (13) Pregnant patients, patients in lactating, and patients want to become pregnant during test period. (14) Patients who participated in the other interventions tested within 16 weeks prior to study drug administration. (15) Other, patient that investigators or test sharing doctor was ineligible as a subject of the present study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method